Coloring complex shapes decreases patient anxiety in three care environments: a pilot study with color analysis.

Introduction: This study was conducted to determine the effectiveness of coloring activity of circular symmetrical shape with complex patterns, so-called mandala, on anxiety associated with chronic illness in three different ambulatory medical situations (general consultation, psychiatric day hospital, and hemodialysis session). Methods: Thirty patients were included in three groups and came from three different ambulatory medical situations: a hemodialysis group (n = 10), a psychiatric day hospital group (n = 10), and a nephrology consultation group (n = 10). We asked the patients to fill STAI-S and STAI-T questionnaires before to color complex circular shape with complex patterns, then to fill the STAI-S questionnaire again and a questionnaire on the experience of the activity. Results: The results show that the STAI-S score was significantly lower after coloring for the hemodialysis (p = 0.02) and psychiatric groups (p = 0.005) but not for the general consultation group (p = 0.26). STAI-T scores did not differ between groups. The distribution of colors in the mandala was different in the three groups of patients. A positive subjective experience of the activity was found in all groups. Discussion: These results show the effectiveness of a coloring activity of a circular shape with complex patterns on anxiety associated with chronic illness in care environment. The different distribution of the colors of the mandala in the three groups raises the question of the influence of the context on the mood of the patients and the deeper meaning of the choice of colors and their placement in the mandala. Our study reinforces the multiple applications of art activities in different medical disciplines and encourages their development within healthcare settings.

Iatrogenic encephalopathies are not so rare in psychiatry: A retrospective study about 5217 EEG examinations.

OBJECTIVES: Encephalopathy is a severe pathological process induced by multiple factors, which is typically associated with electroencephalogram (EEG) abnormalities. Early diagnosis, management, and treatment improve the patient's prognosis. Psychotropic treatments are a risk for drug-induced encephalopathies. In this study, the prevalence of encephalopathies in a psychiatric hospital has been studied for 5 years (2012 to 2016) using 5217 EEG records. METHODS: EEGs were performed i) systematically on patient admission, ii) in response to inexplicable modifications of consciousness or behavior, or when metabolic anomalies occurred, and iii) to perform therapeutic monitoring in outpatient consultations. When encephalopathy was suspected, the clinical data (age, sex and concomitant treatment) and biological data (plasma levels of medications) were collected. RESULTS: Encephalopathy was suspected in 189 patients. Following EEG examination, and monitoring of clinical course, encephalopathy was subsequently determined to be highly probable for 52 patients, (giving a prevalence of 1% per year), and low suspicion of encephalopathy in the other 137 patients. The suspicion of encephalopathy was made on both clinical (n=28) and non-clinical (n=24) signs. Involved drugs were mainly valproic acid (n=14), lithium (n=11) and clozapine (n=11) in the highly probable encephalopathy group. CONCLUSIONS: Our study demonstrates the importance of EEG in the diagnosis and monitoring of encephalopathies in a psychiatric hospital. Clinical symptoms of encephalopathies are polymorphic and sometimes atypical. This diagnosis is underestimated in a context where behavior or consciousness disorders are generally not attributed to psychotropic drugs used in psychiatry.

Electroencephalogram Modifications Associated With Atypical Strict Antipsychotic Monotherapies.

BACKGROUND: Antipsychotics produce electroencephalogram (EEG) modifications and increase the risk of epileptic seizure. These modifications remain sparsely studied specifically for atypical antipsychotics. In this context, our study focuses on EEG modifications associated with atypical strict antipsychotic monotherapies. METHODS: Electroencephalogram recordings of 84 psychiatric patients treated with atypical antipsychotics in strict monotherapy (clozapine, n = 22; aripiprazole, n = 22; olanzapine, n = 17; risperidone, n = 9; quetiapine, n = 8; risperidone long-acting injection, n = 4; and paliperidone long-acting injection, n = 2) were analyzed. The modifications were ranked according to both slowing and excitability scores. RESULTS: Electroencephalogram modifications (in 51 subjects, 60.71%) were graded according to 4 stages combining general slowing and sharp slow waves and/or epileptiform activities. The presence of sharp or epileptiform activities was significantly greater for clozapine (90.9%) compared with other second-generation antipsychotics (aripiprazole, 50%; olanzapine, 58.8%; quetiapine, 37.5%; risperidone, 44.4%). Age, duration of disease progression, and diagnosis were not associated as risk factors. Electroencephalogram modifications were associated with lower doses for treatment with quetiapine but not for specific antipsychotics. Electroencephalogram modifications and severe excitability were associated with higher chlorpromazine equivalent doses. CONCLUSIONS: Atypical antipsychotics (clozapine, aripiprazole, quetiapine, olanzapine, and risperidone) induce EEG modifications, and these are significantly greater for clozapine and appear dependent on chlorpromazine equivalent dose. No encephalopathy was observed in these antipsychotic monotherapies, whatever dose.